Brief: Kronos Bio And Invivoscribe Partner On Companion Diagnostic
16/08/2022 23:11
Aug 16 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO AND INVIVOSCRIBE PARTNER ON COMPANION
DIAGNOSTIC FOR
USE WITH ENTOSPLETINIB, KRONOS BIO'S INVESTIGATIONAL COMPOUND
BEING DEVELOPED FOR PATIENTS WITH AML
* KRONOS BIO INC - ENTOSPLETINIB IS CURRENTLY BEING STUDIED
IN
PHASE 3 AGILITY REGISTRATIONAL STUDY, WITH DATA ANTICIPATED IN
SECOND HALF OF 2023
Source text for Eikon: ID:nCNWYRyFna
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems